FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1938975637> ?p ?o ?g. }

• W1938975637 endingPage "16" @default.
• W1938975637 startingPage "9" @default.
• W1938975637 abstract "Abstract Psoriasis is a chronic, genetically predisposed skin disorder, characterised by thickened scaly plaques. Although no therapy is recognised as curative, therapies aimed at symptom control include biologic agents that are generally designed to block molecular activation of cellular pathways of a pathogenic immune response. Although biologics are often described as a class, they can be further sub‐classified according to properties including structure and molecular target. For example, the two main groups of biologics for the treatment of psoriasis are those targeting cytokines and those targeting T‐cells or antigen‐presenting cells. Agents that inhibit cytokines can be broadly split into anti‐p40 agents, which target the p40 subunit of IL‐12 and IL‐23 (such as ustekinumab), and anti‐TNF agents. Anti‐TNF agents may then be further divided into soluble receptors (etanercept) and monoclonal antibodies (adalimumab and infliximab). Even within the same subclass, agents may display variations in structure, function, route of administration and pharmacokinetics, which are reflected in their clinical profiles. For example, of the TNF antagonists, infliximab, provides a rapid onset of response, high efficacy, high peak serum concentrations, anti‐granulomatous activity, potential for tuberculosis reactivation and frequent antibody formation; adalimumab provides a fast response, high efficacy, potential for tuberculosis reactivation and the possibility of antibody formation; and etanercept provides a slower response, good efficacy, rare antibody formation and is rarely linked to tuberculosis cases. This suggests that biologic agents exhibit unique properties, which appear to be more relevant than a ‘class effect’ in assessing risk‐benefit profiles for this diverse group of drugs. With a range of agents available, studying the immunogenesis of psoriasis is likely to be useful in profiling individuals best suited to the characteristics of particular drugs. It should also be noted that because differences between agents may affect safety profiles, long‐term patient registries are an important tool to assess tolerability and develop guidelines for the most effective use of these drugs." @default.
• W1938975637 created "2016-06-24" @default.
• W1938975637 creator A5018780132 @default.
• W1938975637 creator A5064403166 @default.
• W1938975637 date "2012-07-03" @default.
• W1938975637 modified "2023-10-02" @default.
• W1938975637 title "Is ‘class effect’ relevant when assessing the benefit/risk profile of a biologic agent?" @default.
• W1938975637 cites W1583226605 @default.
• W1938975637 cites W1967303616 @default.
• W1938975637 cites W1970875728 @default.
• W1938975637 cites W1971242419 @default.
• W1938975637 cites W1972194503 @default.
• W1938975637 cites W1996502174 @default.
• W1938975637 cites W2000902902 @default.
• W1938975637 cites W2006673542 @default.
• W1938975637 cites W2013361256 @default.
• W1938975637 cites W2027978561 @default.
• W1938975637 cites W2030348118 @default.
• W1938975637 cites W2033275545 @default.
• W1938975637 cites W2034585843 @default.
• W1938975637 cites W2036488279 @default.
• W1938975637 cites W2037908022 @default.
• W1938975637 cites W2062606699 @default.
• W1938975637 cites W2062822873 @default.
• W1938975637 cites W2068281838 @default.
• W1938975637 cites W2069350424 @default.
• W1938975637 cites W2070353058 @default.
• W1938975637 cites W2071652319 @default.
• W1938975637 cites W2091442391 @default.
• W1938975637 cites W2106686862 @default.
• W1938975637 cites W2110441300 @default.
• W1938975637 cites W2116956799 @default.
• W1938975637 cites W2126457303 @default.
• W1938975637 cites W2129137973 @default.
• W1938975637 cites W2129412675 @default.
• W1938975637 cites W2133542467 @default.
• W1938975637 cites W2146843653 @default.
• W1938975637 cites W2151566115 @default.
• W1938975637 cites W2152976783 @default.
• W1938975637 cites W2168911501 @default.
• W1938975637 cites W2172257129 @default.
• W1938975637 cites W4234254272 @default.
• W1938975637 cites W4236396577 @default.
• W1938975637 cites W4245698794 @default.
• W1938975637 doi "https://doi.org/10.1111/j.1468-3083.2012.04605.x" @default.
• W1938975637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22758912" @default.
• W1938975637 hasPublicationYear "2012" @default.
• W1938975637 type Work @default.
• W1938975637 sameAs 1938975637 @default.
• W1938975637 citedByCount "8" @default.
• W1938975637 countsByYear W19389756372013 @default.
• W1938975637 countsByYear W19389756372014 @default.
• W1938975637 countsByYear W19389756372015 @default.
• W1938975637 countsByYear W19389756372017 @default.
• W1938975637 countsByYear W19389756372023 @default.
• W1938975637 crossrefType "journal-article" @default.
• W1938975637 hasAuthorship W1938975637A5018780132 @default.
• W1938975637 hasAuthorship W1938975637A5064403166 @default.
• W1938975637 hasConcept C142724271 @default.
• W1938975637 hasConcept C147483822 @default.
• W1938975637 hasConcept C159654299 @default.
• W1938975637 hasConcept C17991360 @default.
• W1938975637 hasConcept C203014093 @default.
• W1938975637 hasConcept C2777138892 @default.
• W1938975637 hasConcept C2777226972 @default.
• W1938975637 hasConcept C2778975655 @default.
• W1938975637 hasConcept C2780132546 @default.
• W1938975637 hasConcept C2780564577 @default.
• W1938975637 hasConcept C2781069245 @default.
• W1938975637 hasConcept C2781290027 @default.
• W1938975637 hasConcept C542903549 @default.
• W1938975637 hasConcept C71924100 @default.
• W1938975637 hasConcept C8891405 @default.
• W1938975637 hasConceptScore W1938975637C142724271 @default.
• W1938975637 hasConceptScore W1938975637C147483822 @default.
• W1938975637 hasConceptScore W1938975637C159654299 @default.
• W1938975637 hasConceptScore W1938975637C17991360 @default.
• W1938975637 hasConceptScore W1938975637C203014093 @default.
• W1938975637 hasConceptScore W1938975637C2777138892 @default.
• W1938975637 hasConceptScore W1938975637C2777226972 @default.
• W1938975637 hasConceptScore W1938975637C2778975655 @default.
• W1938975637 hasConceptScore W1938975637C2780132546 @default.
• W1938975637 hasConceptScore W1938975637C2780564577 @default.
• W1938975637 hasConceptScore W1938975637C2781069245 @default.
• W1938975637 hasConceptScore W1938975637C2781290027 @default.
• W1938975637 hasConceptScore W1938975637C542903549 @default.
• W1938975637 hasConceptScore W1938975637C71924100 @default.
• W1938975637 hasConceptScore W1938975637C8891405 @default.
• W1938975637 hasIssue "s5" @default.
• W1938975637 hasLocation W19389756371 @default.
• W1938975637 hasLocation W19389756372 @default.
• W1938975637 hasOpenAccess W1938975637 @default.
• W1938975637 hasPrimaryLocation W19389756371 @default.
• W1938975637 hasRelatedWork W1597227996 @default.
• W1938975637 hasRelatedWork W1920699911 @default.
• W1938975637 hasRelatedWork W2014044177 @default.
• W1938975637 hasRelatedWork W2031552244 @default.
• W1938975637 hasRelatedWork W2062801585 @default.

• next